The listing below shows our latest News Items and is updated regularly. If you wish to post a news item please select the 'Post News' button on the right. The displayed news feed starts on 1st August 2016. Older items can be found here.
To 'Post Your News' use the button at the top right.
11 August 2016: London, UK - Bio-start, an annual competition designed to bolster UK companies aiming to solve significant global problems through synthetic biology has been launched.
Read the rest of entry »
11 August 2016: Philadelphia, USA – The successful development and manufacturing of highly potent molecules is the theme of the next free, specialist webinar from leading pharmaceutical outsourcing provider PCI Pharma Services (Thursday, September 8, 10am EDT / 3pm GMT).
Oxford, UK, - Summit Therapeutics plc, the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD') and Clostridium difficile infection, today reports Phase 1 clinical trial results that show a new formulation of ezutromid (referred to as 'F6') achieved a greater than six-fold increase in maximum plasma levels in DMD patients compared to those achieved with the current clinical formulation (referred to as 'F3') with only two fifths of the dose.
UK businesses could win a share of £1.2 million to carry out short, international cooperation feasibility studies. UK businesses looking to create international business networks can apply for funding of up to £21,000. This funding is to enable commercial research and innovation partnerships. It will also help businesses explore ideas for future collaboration.
04 August 2016: Guildford, UK & Houston, USA - ANGLE plc, the specialist medtech company, announces a poster presentation by researchers from the University of Texas MD Anderson Cancer Center describing clinically-relevant results from a study using its lead product, the Parsortix cell separation system, to harvest breast cancer cells in blood for subsequent molecular characterisation. The poster was presented at the American Association for Clinical Chemistry Annual Meeting on 2 August 2016.
04 August 2016: Oxford, UK - Chronos Therapeutics Ltd, the private biotech company focused on ageing diseases, brain and nervous system disorders, today announced the appointment of Dr Fraser Murray and Dr Timothy Schulz-Utermoehl, as Vice Presidents of Pre-Clinical Development.
03 August 2016: Cardiff, UK & Philadelphia, USA – Leading pharmaceutical outsourcing services provider PCI Pharma Services (PCI) has announced the appointment of Sue Ritchie and Fred Schulze to its US sales team, with business development responsibility for PCI’s expanding global development and manufacturing capability.
03 August 2016: Abingdon, UK, OBN Ltd, the membership organisation supporting the UK’s innovative life sciences companies, today announces the finalists of its 8th Annual Awards covering Biotech, Medtech, Synthetic Biology and Digital Health. The OBN Awards remain proudly independent, celebrating innovation and achievement across the UK life sciences industry and recognising achievements from emerging to late stage R&D companies as well as life sciences investors.
02 August 2016: Oxford, UK & Marlborough, USA - Oxford Immunotec Global PLC, a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced second quarter 2016 financial results.
02 August 2016: Gosport, UK - Wickham Laboratories Ltd is pleased to announce the publication of a joint study with Bioquell on the efficacy of disinfection by hydrogen peroxide.
OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.
This is an impromptu noticeboard to let people know about events, other things that are happening, perhaps lab equipment for sale etc. Just drop an email to us, firstname.lastname@example.org, and we will post.